Posted by Michael Wonder on 09 Dec 2018
Zaxine (rifaximin) - now indicated in Canada for patients with irritable bowel syndrome with diarrhoea
6 December 2018 - Lupin Pharma Canada is pleased to announce the approval from Health Canada for Zaxine 550 mg (rifaximin) for the treatment of irritable bowel syndrome with diarrhoea in adults.
Zaxine for irritable bowel syndrome with diarrhoea is being launched in December of 2018 under a strategic licensing agreement with Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases.
The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in Canada. This is in addition to Zaxine's previously approved indication for the reduction in risk of overt hepatic encephalopathy in adults.
